NCT06827782 is a Phase 1 clinical trial of anti-CD19 CAR-NK cells in Refractory/Recurrent Central Nervous System Lymphoma, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

Who is sponsoring NCT06827782?

NCT06827782 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

What drugs are being tested in NCT06827782?

Interventions in NCT06827782: anti-CD19 CAR-NK cells.

What condition does NCT06827782 study?

NCT06827782 studies Refractory/Recurrent Central Nervous System Lymphoma.

Is NCT06827782 still recruiting?

NCT06827782 is currently enrolling by invitation. Last updated 15 August 2025.

Last reviewed 2025-08-15 · How we verify

NCT06827782

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma

ENROLLING BY INVITATION Phase 1 Last updated 15 August 2025

What this trial tests

Phase 1 trial testing anti-CD19 CAR-NK cells in Refractory/Recurrent Central Nervous System Lymphoma in 42 participants. Enrolling by invitation.

Timeline

1 March 2025

Primary endpoint
31 December 2026

31 December 2028

Quick facts

Lead sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase	Phase 1
Status	ENROLLING BY INVITATION
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	42
Start date	1 March 2025
Primary completion	31 December 2026
Estimated completion	31 December 2028
Sites	1 location across China

Drugs / interventions tested

anti-CD19 CAR-NK cells

Conditions studied

Refractory/Recurrent Central Nervous System Lymphoma — all drugs for Refractory/Recurrent Central Nervous System Lymphoma →

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

Adults 18 to 75, any sex, with Refractory/Recurrent Central Nervous System Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed to evaluate the safety and efficacy of cord blood-derived CAR-NK019 in the treatment of refractory/relapsed central nervous system lymphoma.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Natural killer cells in adoptive cell therapy: current landscape of genetic engineering strategies.
Burón M, Etxebarria A, Álvarez M, Romayor I, et al · · 2025 · cited 4× · PMID 40996824 · DOI 10.1080/2162402x.2025.2563099
Mechanisms of Resistance to CAR T-Cells and How to Overcome Them.
Legato L, Bisio M, Fasano F, Benevolo Savelli C, et al · · 2025 · cited 3× · PMID 40981226 · DOI 10.3390/mps8050108
Strategies for the Development of NK Cell-Based Therapies for Cancer Treatment.
Budagova T, Efremova A, Maiak M, Goldshtein D. · · 2025 · cited 1× · PMID 41369346 · DOI 10.3390/cells14231858
Chimeric antigen receptor natural killer (CAR-NK) cells: from preclinical promise to clinical reality in cancer immunotherapy.
Cochran HC, Ghobadi KA, Ghobadi A. · · 2025 · PMID 41186143 · DOI 10.1080/1750743x.2025.2582464

Verify or expand the search:

Other trials of anti-CD19 CAR-NK cells

Trials testing the same drug.

NCT06421701 — Anti-CD19 CAR-NK Cells in Refractory/Relapsed Systemic Lupus Erythematosus · Phase 1 · recruiting

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06827782 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
Last refreshed: 15 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06827782.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing